辰欣药业上涨7.49%，报32.45元/股

Core Viewpoint - On August 4, Chenxin Pharmaceutical experienced a stock price increase of 7.49%, reaching 32.45 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 8.5%, resulting in a total market capitalization of 14.692 billion CNY [1] Company Overview - Chenxin Pharmaceutical Co., Ltd. is located in Jining High-tech Zone, Tongji Technology Industrial Park, and is a comprehensive pharmaceutical enterprise engaged in research and development, production, and sales [1] - The company focuses on independently developing and producing drugs that fill domestic gaps, allocating 6% of its annual sales revenue to R&D investments [1] - Chenxin has successfully developed drugs such as Adefovir Dipivoxil and has established long-term cooperative relationships with several research institutions [1] Financial Performance - For the period from January to March 2025, Chenxin Pharmaceutical reported an operating income of 920 million CNY, a year-on-year decrease of 19.91% [1] - The net profit attributable to shareholders was 144 million CNY, reflecting a year-on-year decrease of 11.86% [1] - As of March 31, the number of shareholders was 21,400, with an average of 21,200 circulating shares per person [1]